Partnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand
ZIVO Bioscience, Inc. (OTCQB: ZIVO) , today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders,...
ZIVO Bioscience, Inc. (OTCQB: ZIVO) , a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the...
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary...
March S&P 500 futures (ESH23) are trending up +0.06%, and March Nasdaq 100 E-Mini futures (NQH23) are up +0.37% this morning as investors look ahead to crucial U.S. inflation data due this week for more...
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary...
Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary...
Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today...
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary...
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary...